총 710건

해외임상승인현황 정보 :: 순번, 임상시험 제목, 적응증, 연구설계, 의뢰자/실시기관, 임상단계, 게시일자
순번 임상시험 제목 적응증 연구설계 의뢰자/실시기관 임상단계 게시일자
1 An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease Non-Small Cell Lung Cancer|Non-Small-Cell Lung Carcinoma|Circulating Tumor DNA Biological: Nivolumab|Drug: Vinorelbine|Drug: Gemcitabine|Drug: Docetaxel|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin|Drug: Paclitaxel|Other: Observation Bristol-Myers Squibb Phase 2 2020-06-15
2 Gene Therapy for Achromatopsia (CNGA3) Achromatopsia Biological: AAV- CNGA3 MeiraGTx UK II Ltd Phase 1|Phase 2 2019-07-18
3 Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV Respiratory Syncytial Virus Infections Biological: Respiratory syncytial virus (RSV) vaccine GSK3389245A|Biological: Bexsero|Biological: Nimenrix|Biological: Menveo|Biological: Synflorix|Drug: Placebo GlaxoSmithKline Phase 1 2019-04-08
4 A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy Psoriatic Arthritis Biological: placebo for rizankizumab|Biological: risankizumab AbbVie Phase 3 2019-03-25
5 A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) Psoriatic Arthritis Biological: placebo for rizankizumab|Biological: risankizumab AbbVie Phase 3 2019-03-07
6 A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis Generalized Pustular Psoriasis Drug: ANB019 AnaptysBio, Inc. Phase 2 2019-03-04
7 Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma Hepatocellular Carcinoma Biological: Ipilimumab|Biological: Nivolumab Imperial College London|Bristol-Myers Squibb Phase 1|Phase 2 2019-03-01
8 PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer Breast Neoplasm Drug: AZD6738|Drug: Olaparib|Drug: Durvalumab Institute of Cancer Research, United Kingdom|AstraZeneca Phase 2 2019-02-01
9 A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease Huntingtons Disease Drug: RO7234292|Drug: Placebo Hoffmann-La Roche Phase 3 2019-01-23
10 A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age Respiratory Syncytial Virus Biological: Ad26.RSV.preF|Biological: Placebo|Biological: Nimenrix Janssen Vaccines & Prevention B.V. Phase 1|Phase 2 2019-01-21